Walnut Creek, CA, United States of America

Carl T Redmann

This inventor holds 1 USPTO granted patent. Top assignee: Liposome Technology, Inc.. Active years: 1989.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 73(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Carl T. Redmann

Introduction

Carl T. Redmann is a notable inventor based in Walnut Creek, California. He has made significant contributions to the field of ophthalmic drug delivery through his innovative work on liposome technology. His research focuses on enhancing the effectiveness of treatments for dry eye conditions.

Latest Patents

Carl T. Redmann holds a patent for "Ophthalmic liposomes," which describes a liposome composition designed for improved retention on ocular surfaces. This invention is particularly useful in ophthalmic drug delivery and addresses the challenges associated with dry eye treatment. The liposomes are formulated with a specific lipid composition that includes an amine-derivatized lipid component, ensuring optimal performance in drug delivery applications.

Career Highlights

Throughout his career, Redmann has been associated with Liposome Technology, Inc., where he has furthered his research and development efforts. His work has led to advancements in the formulation of liposomes, which are crucial for effective ocular treatments.

Collaborations

He has collaborated with notable colleagues such as Luke S. Guo and Ramachandran Radhakrishnan, contributing to the collective knowledge and innovation in the field of liposome technology.

Conclusion

Carl T. Redmann's contributions to ophthalmic drug delivery through his patented innovations highlight his role as a key figure in the field. His work continues to influence the development of effective treatments for dry eye conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…